Knowledge Hub

  • Reset

Exercise in Inherited Cardiomyopathies: Optimising the Dose-Response Curve

Exercise in Inherited Cardiomyopathies: Optimising the Dose-Response Curve Rye EE, Mitchell AM, Santiago CF, La Gerche A, Fatkin D. Exercise

AHA 2023 Treatment Strategies for Cardiomyopathy in Children

Diagnosis and management considerations in paediatric cardiomyopathy. AHA 2023 Treatment Strategies for Cardiomyopathy in Children

2024 International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates

2024 International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates

EMQN: Recommendations for genetic testing in inherited cardiomyopathies and arrhythmias

2023 framework for genetic counselling and testing in inherited cardiovascular diseases. EMQN: Recommendations for genetic testing in inherited cardiomyopathies and

Heart Foundation of Australia: Additional resources to support patients with heart failure

Heart Foundation of Australia: Additional resources to support patients with heart failure Developed based on the Guidelines for the prevention,

Heart Foundation of Australia / Cardiac Society of Australia and New Zealand (CSANZ) Clinical Guidelines for the Diagnosis and Management of Heart Failure (2018)

Nationally endorsed guideline aligning with Australian practice, referral pathways, and available therapies. Heart Foundation of Australia / Cardiac Society of

ESC 2021 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

European counterpart addressing diagnostic algorithms, imaging, comorbidities, and management of heart failure with reduced and preserved ejection fraction. ESC 2021

ACC / AHA / HFSA 2022 Guideline for the Management of Heart Failure

Comprehensive guidance on diagnosis, classification, and management of heart failure, including updated pharmacological therapy (ARNI, SGLT2 inhibitors), devices, and advanced

ESC Peripartum Cardiomyopathy Position Statement (2020)

Diagnosis, management, and counselling for future pregnancies. ESC Peripartum Cardiomyopathy Position Statement (2020)

AHA / ACC 2024 Guideline for the Management of Hypertrophic Cardiomyopathy

Updates the 2020 guideline with revised diagnostic criteria, risk stratification, and management including new pharmacological therapies and genetic counselling guidance.

Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis (2024)

Regionally tailored recommendations on investigation, diagnosis, and management of cardiac amyloidosis, incorporating local service structures and therapy access. Australia–New Zealand

ESC Working Group Position Statement: Diagnosis and Treatment of Cardiac Amyloidosis (2021) 

Outlines red flags for suspicion, diagnostic pathways, imaging, biopsy, and management of cardiac amyloidosis subtypes (ATTR-CM and AL-CM). ESC Working

Heart Rhythm Society (HRS) / American College of Cardiology (ACC) / American Heart Association (AHA) 2019 Expert Consensus on Arrhythmogenic Cardiomyopathy 

Provides detailed guidance on genetic evaluation, arrhythmia risk stratification, ICD therapy and exercise restriction in arrhythmogenic cardiomyopathy.

European Society of Cardiology (ESC) 2023 Guidelines for the Management of Cardiomyopathies

Covers all forms of cardiomyopathy across the life course, including hypertrophic, dilated, restrictive, arrhythmogenic and non-dilated left ventricular cardiomyopathy. Focuses